Snapshot · Huberman Lab
A single brain area — the inferior parietal lobule — is uniquely activated by changes in physical spacing, temporal spacing, and emotional closeness, forming the neural basis of all attachment.
Where this was said
At 7:18 · chapter starts 7:05
Huberman pauses here to make sure the listener grasps the magnitude of the finding: the inferior parietal lobule is not just involved in one type of closeness — it is the brain's single hub for all three. Physical proximity (where someone sits in the room), temporal proximity (when you last spoke and when you expect to again), and emotional closeness (how deeply bonded you are) are not stored in separate brain regions but are braided together into one unified map. This interlocking architecture explains why attachment is so powerful and — crucially — why disrupting one dimension (someone dies, so their spatial and temporal coordinates become undefined) destabilizes the entire map. [1] — Andrew Huberman "The brain encodes every relationship across three dimensions — physical space, time (when you expect to see them), and emotional closeness …" 00:35 The attachment does not disappear; it simply loses its two anchor points in space and time, leaving it unmoored and searching. This is the neurological condition that we call grief.
Animals first sensed light 540 million years ago, triggering an evolutionary acceleration known as the Cambrian explosion within 10 million years.
It is estimated that half of all cortical activity in the human brain is involved in visual function, underscoring vision's central role in intelligence.
Cognitive neuroscience literature shows that by age 6, humans can recognize tens of thousands of different object categories — far more data than early AI systems were trained on.
Only about 3% of FDA-approved drugs have genuinely unclear mechanisms of action, making an unknown mechanism a meaningful early red flag for any compound.
Even compounds that clear preclinical testing often fail in humans: 30 to 50% of drugs entering phase 1 trials do not advance to phase 2, frequently because human behavior differs from animal models.
More than 80% of published BPC-157 research comes from a single academic group whose researchers have IP and commercial interests connected to the molecule, limiting independent replication.
Roughly 100 peptide drugs are already FDA-approved, about 150 more are in clinical trials, and 600–700 are in preclinical development, underscoring the legitimacy of peptide science broadly.
The scientist who discovered BPC-157 refused to disclose the screening method used to identify the compound and has never fully published the parent protein sequence — what Peter Attia calls 'scientific trust me, bro.'
The brain's visual, auditory, and motor cortices light up nearly identically whether an experience is real or imagined, making visualization a form of actual neural training.
We use essential and analytics cookies to run Vuci. To understand how the site is used: Privacy Policy.
Install Vuci on your phone
Add it to your home screen for a faster, app-like experience.
Install Vuci on your phone
Tap the Share button, then “Add to Home Screen”.
A new version is available
Reload to get the latest Vuci.